News Releases

NEW YORK, NEW YORK--(Marketwired - Dec. 9, 2016) - BMO Capital Markets, the investment and corporate banking arm of BMO Financial Group (NYSE:BMO)(TSX:BMO), will hold its inaugural Prescriptions for Success Healthcare Conference on December 14^th at the Barclay's Intercontinental Hotel in New York.

This year's conference comes as the biopharma industry faced significant pressure from drug pricing and reimbursement for much of 2016, and the recent U.S. presidential election raised questions about the outlook for Obamacare and drug pricing. Through a series of fireside chats and panel discussions, key pharmaceutical and biotech companies will discuss topics ranging from pricing pressure and drug reimbursement to what a brighter future may hold in terms of innovative pipeline opportunities.

"2016 has been a year of change and challenge for the entire healthcare industry and in particular for pharma and biotech. All of this has weighed on investor sentiment for much of the year and we expect our conference will improve investors' ability to navigate through a challenging environment in the year ahead to find good investment opportunities," said BMO Capital Markets Analyst Gary Nachman. Mr. Nachman will co-host the conference with fellow BMO Research Analyst Ian Somaiya.

"In addition to our general optimism post-election, we think we could be heading into a year of increased M&A activity in biopharma. We believe acquirers may be less price-sensitive if repatriation is more likely, potentially supporting a range of mid-to-larger cap deals. However, based on our analysis of historical acquisition multiples, we believe smaller-cap, bolt-on acquisitions are more likely in the near term, until Mr. Trump's tax policy strategies are better known," said Mr. Somaiya.

The BMO Capital Markets Prescriptions for Success Healthcare Conference will feature prominent executives from biotech and pharmaceutical companies, including CEOs, CFOs, COOs and CSOs from a wide range of major publicly traded companies, as well as from exciting and innovative private companies.

Other highlights include two panel discussions on the critical topics of drug reimbursement and the new generation of "orphan drugs." Senior executives from more than 30 leading companies will participate in fireside chats including:

• AveXis (AVXS)
• Horizon Pharma (HZNP)
• Intercept Pharmaceuticals (ICPT)
• Ionis Pharmaceuticals (IONS)
• Jazz Pharmaceuticals (JAZZ)
• Mallinckrodt Pharmaceuticals (MNK)
• Neurocrine Biosciences (NBIX)
• Valeant Pharmaceuticals International (VRX)

Media Registration:

Media who wish to attend the conference, in person, can register directly by clicking here. For those who wish to access portions of the conference that are webcast, please email the BMO Capital Markets media team.

About BMO Capital Markets

BMO Capital Markets is a leading, full-service North American financial services provider. With more than 2,400 employees operating in 30 locations, including 16 in North America, BMO Capital Markets offers corporate, institutional and government clients access to a complete range of investment and corporate banking products and services. BMO Capital Markets is a member of BMO Financial Group (NYSE:BMO)(TSX:BMO), one of the largest diversified financial services providers in North America, with total assets of CDN $687.9 billion as of October 31, 2016, and over 45,000 employees.